Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat  by Bover, Jordi et al.
Kidney International, Vol. 45 (1994), pp. 953—961
LABORATORY INVESTIGATION
Factors in the development of secondary hyperparathyroidism
during graded renal failure in the rat
J0RDI BOVER, MARIANO RODRIGUEZ,' PEDRO TRINIDAD,2 AQUILES JARA,
MARIA E. MARTINEZ,3 LoR1tINE MACHADO, FRANCISCO LLACH,
and ARNOLD J. FELSENFELD
Department of Medicine, Wadsworth VAMC and UCLA, Los Angeles, California, USA
Factors in the development of secondary hyperparathyroidism during
graded renal failure in the rat. Secondary hyperparathyroidism (2° HPT)
develops as a result of renal failure. Hypocalcemia, phosphorus reten-
tion, calcitnol deficiency and skeletal resistance to the calcemic action
of parathyroid hormone (PTH) are closely interrelated pathogenic
factors important for the development of 2° HPT in renal failure. Since
previous studies have mainly focused on advanced renal failure, only
limited data are available in early renal failure. The goal of the present
study was to evaluate how alterations in the dietary calcium and
phosphorus composition affect the factors known to contribute to the
genesis of 2° HPT in early and more advanced renal failure. To achieve
this goal, graded differences in renal function were surgically induced in
453 rats while the dietary content of calcium and phosphorus was
varied. Three different diets were used: (1) a high phosphorus diet
(HPD), to induce phosphorus retention and stimulate 2° HPT; (2) a high
calcium diet (HCaD), to inhibit calcitriol synthesis; and (3) a moderate
calcium-moderate phosphorus diet (MCaPD), to separate the effects of
high dietary phosphorus and calcium. Based on the serum creatinine
(Scr) concentration rats were assigned to one of four different groups:
(1) normal renal function (Sr 0.3 mg/dl); (2) mild renal failure (Sr 0.4
to 0.6 mg/dl); (3) moderate renal failure (Se. 0.7 to 0.8 mg/dl); or (4)
advanced renal failure (Se.  0.9mg/dl). As the severity of renal failure
increased, progressive 2° HPT developed in each of the dietary groups.
In the HPD group, the increase in PTH in normals from 47 2 to 135
14 pg/mI in mild renal failure (P < 0.001) was associated with hyper-
phosphatemia, a decrease in calcitriol and a decreased calcemic re-
sponse to PTH. In the HCaD group, the increase in PTH in normals
from 42 2 to 74 4 pg/mI in mild renal failure (P < 0.001) was
associated with a decrease in calcitriol. In the MCaPD group, 2° HPT
developed (40 2 vs. 70 4 pg/ml, normals vs. mild renal failure, P <
0.001) despite normal serum calcium, phosphorus and calcitriol levels;
however, a decreased calcemic response to PTH was observed. In
advanced renal failure, progressive increases of PTH were observed in
all groups, but PTH levels were approximately three-fold greater in the
HPD than the HCaD and MCaPD groups (410 24, 114 14 and 138
17 pg/mI, respectively; P < 0.001). While serum calcitriol levels were
markedly decreased in the HPD and HCaD groups in advanced renal
failure, normal calcitriol levels were present in the MCaPD group. In
summary, the development and magnitude of 2° HPT in the HPD group
could be best explained by the contribution of several additive factors
which included: hypocalcemia, phosphorus retention, a calcitriol defi-
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ciency and a decreased calcemic response to PTH. In the HCaD group,
a calcitriol deficiency appeared to be the most important factor for the
development of 2° HPT. In the MCaPD group, a decreased calcemic
response to PTH, which may have been due to uremia, was the only
factor to which 2° HPT could be attributed.
Considerable effort has been devoted to identifying the fac-
tors which are important for the genesis of secondary hyper-
parathyroidism (2° HPT) in renal failure. These factors include:
(1) hypocalcemia [1—41; (2) phosphorus retention [1, 2, 5]; (3) a
deficiency of calcitriol [6, 71;and (4) skeletal resistance to the
calcemic action of parathyroid hormone (PTH) [8—111. Since
these pathogenic factors are closely interrelated, evaluating the
independent effect of each factor is often difficult. Hypocalce-
mia and a calcitriol deficiency have been shown to directly
stimulate PTH synthesis and secretion [4, 6, 12, 13]. Both
phosphorus retention [10, 14] and a calcitriol deficiency [81
independently contribute to the decreased calcemic response to
PTH. Phosphorus retention has also been shown to induce
hypocalcemia [10, 15] and decrease calcitriol production [16—
18]. Furthermore, Lopez-Hilker et al have even suggested that
phosphorus retention may directly stimulate PTH secretion
[19]. Finally, since the genesis of 2° HPT is multifactorial, it is
likely that much of the reported contradictory data regarding
the genesis of 2° HPT in the early stages of renal failure may be
due to differences in the combination of factors contributing to
the development of 2° HPT.
Despite the large body of information on the pathogenesis of
2° HPT, this information generally lacks an integrative ap-
proach; this is especially true in early renal failure in which only
limited data are available. During the past several years we
have developed an experimental model in the rat in which the
degree of surgically induced renal failure can be controlled [10,
11]. Thus, our goal in the present study was to evaluate in
different stages of renal failure, how changes in dietary calcium
and phosphorus composition affect the factors known to be
important for the the development and magnitude of 2° HPT. To
accomplish this goal, we performed a series of studies in which
the dietary calcium and phosphorus intake was varied in normal
rats and in azotemic rats with graded degrees of renal failure. In
addition, the calcemic response (CR) to PTH which has not
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been determined in most studies addressing the pathogenesis of
2° HPT was evaluated in rats with early renal failure.
Methods
Male Wistar rats weighing 120 to 160 grams were selected for
study. All rats underwent arterial ligation of the left kidney or
sham operation. To obtain different degrees of renal function,
one to three branches of the renal artery in the hilum were
ligated. This was followed one week later by a right nephrec-
tomy or sham operation. During surgical procedures, rats were
anesthetized with 50 mg/kg of sodium pentobarbital (Nembutal,
Abbott Laboratories, Chicago, Illinois, USA) administered
intraperitoneally. Rats were housed in individual cages and
pair-fed; each rat received 12 to 15 grams of food daily and was
allowed free access to water. Rats ingesting less than 12 grams
per day were removed from the study.
Three different diets were used in the 453 rats studied: (1) a
high phosphorus diet (HPD; 0.6% calcium, 1.2% phosphorus) to
induce phosphorus retention and 2° HPT [10, 111; (2) a high
calcium diet (HCaD; 1.2% calcium, 0.6% phosphorus) to inhibit
calcitriol synthesis [20] and to evaluate the effect of high dietary
calcium on the development of 2° HPT; and (3) a moderate
calcium-moderate phosphorus diet (MCaPD; 0.6% calcium,
0.6% phosphorus) to contrast the effects of high dietary phos-
phorus and calcium on the development of 2° HPT. All diets
were provided by the same supplier (ICN, Cleveland, Ohio,
USA) and contained the same vitamin D (100 IU/lOO g of diet)
and caloric content. In general, the calcium and phosphorus
content of our three study diets were in the range stated to be
normal for the rat [21—23]. The only exception was the phos-
phorus content of the high phosphorus diet which was mini-
mally greater than the highest phosphorus content (1%) re-
ported as a normal diet [23]. The study diets were begun
immediately after the right nephrectomy or the corresponding
sham operation. After 16 to 20 days on the respective diets,
blood was obtained after overnight fasting for determination of
serum calcium, phosphorus, creatinine, PTH and calcitriol.
Based on the serum creatinine concentration, rats were as-
signed to one of the four following groups: (1) normal renal
function; serum creatinine  0.3 mg/dl (N = 136 rats); (2) mild
renal failure; serum creatinine 0.4 to 0.6 mg/dl (N = 150 rats);
(3) moderate renal failure; serum creatinine 0.7 to 0,8 mgldl
(N = 90 rats); and (4) advanced renal failure; serum creatinine
0.9 mg/dl (N = 77 rats).
Urinary studies
To assess the relative effect of the different content of dietary
calcium and phosphorus, a 24 hour urine for calcium, phospho-
rus, and creatinine was collected during the last day of the study
diet in a select number of rats with normal renal function and
with mild renal failure. To determine whether dietary changes
induced subtle differences not detected by the measurement of
serum PTH, urinary cyclic AMP, a marker of PTH biological
activity, was measured in rats with normal renal function. For
these urinary studies, rats were housed in individual metabolic
cages and urine was collected for 24 hours.
PTH infusion
To evaluate the importance of the CR to PTH in the early
development of 2° HPT, a 48-hour PTH infusion was performed
in rats with mild renal failure. The use of this method to
determine the calcemic response to PTH has been described in
detail previously [10, 111. Briefly, 1-34 rat PTH (Bachem,
Torrance, California, USA) from a single lot was administered
at a constant rate of 0.11 ug/l00 g body wt/hr using a subcuta-
neously implanted miniosmotic pump (Model 2001, Alza, Palo
Alto, California, USA). The CR to PTH was defined as the
increase in serum calcium (post-infusion minus basal calcium)
after a 48-hour PTH infusion. In our previous studies, rats
received a specific study diet for a specified time period and
then were changed to a calcium-free, low phosphorus (0.16%)
diet during the PTH infusion to evaluate the skeletal response to
F1'H [10, 11]. However, for the present study we reasoned that
the actual response to PTH is modified by the study diet. Thus,
although the response to a PTH infusion during the ingestion of
the study diet reflects both the skeletal response to PTH and gut
absorption of calcium, it more closely resembles the 16 to 20
day period during the induction of 2° HPT in which rats ingested
the study diet.
Serum calcium was measured by atomic absorption (Perkin
Elmer, Norwalk, Connecticut, USA); serum phosphorus, uri-
nary calcium, and urinary phosphorus with specific kits (Sigma,
St. Louis, Missouri, USA); and serum and urinary creatinine
with a creatinine analyzer (Beckman, Fullerton, California,
USA). Serum PTH was determined using a N-terminal radio-
immunoassay (INS, Nichols, San Juan Capistrano, California,
USA); this assay has been validated previously for the deter-
mination of circulating PTH in the rat [10, 11, 24]. The intra-
assay and interassay coefficients of variation were 5.8% and
9%, respectively. Serum calcitriol was measured in 171 rats
using a radioreceptor assay (INS, Nichols); the intraassay and
interassay coefficients of variation were 7.2% and 10.4%, re-
spectively. A previous comparison of this assay with a conven-
tional radioreceptor assay after double column separation
showed a significant correlation approaching identity (r = 0.93,
N 32) [10]. Urinary cyclic AMP was measured with a
conventional radioimmunoassay kit (Incstar, Stillwater, Minne-
sota, USA).
Statistics
Comparisons of the serum data, either among groups with the
same renal function (different diet) or among groups with the
same diet (different renal function) were assessed by ANOVA
followed by the Duncan's multiple comparison test. The rela-
tion between two variables was assessed by Pearson's linear
correlation. Since the urinary data were not normally distrib-
uted, comparisons were performed with non-parametric tests,
the Kruskal-Wallis followed by the Mann Whitney. P values
less than 0.05 were considered significant. Results are ex-
pressed as the mean standard error (SE).
Results
As shown in Table 1, in rats with normal renal function,
serum calcium was similar in the three dietary groups and
serum phosphorus was lower in the HPD than the other two
groups (P < 0.01). The PTH level was higher in the HPD than
the MCaPD group (P < 0.03) and urinary cyclic AMP (Table 2)
greater in the HPD than both the HCaD and MCaPD groups
(73 4 vs. 57 4 and 61 3 pmollmin, respectively, P < 0.01).
Serum calcitriol was lower in the HCaD than the other two
*/ I
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Table 1. Biochemical data for normal renal function and each stage
of renal failure
Serum HPD HCaD MCaPD
Normal renal function
(N = 136) N — 66 N = 40 N — 30
Creatinine mg/dl 0.25 0.01 0.24 0.01 0.25 0.01
Calcium mg/dl 9.9 0.1 9.8 0.1 9.9 0.1
Phosphorus mg/dl 7.6 0.2 8.2 0.2a 8.3 0.2k
PTHC pg/mi
Ca1citrio1' pg/mi
47 2
189 1 1
42 2136 9 40 2185 l7''
Mild renal failure (N
=-150) N=56 N=45 N49
Creatinine mg/di 0.50 0.01 0.50 0.01 0.49 0.01
Calcium mg/dl 9.7 0.1 9.8 0.1 10.0 0.1
Phosphorus mg/di 8.8 0.3 8.0 o.2 77 0.2
PTH pg/mi 135 14 74 4 70 4
Calcitriol pg/mi 152 1 1 88 9 227 1 1ab
Moderate renal failure
(N = 90) N = 46 N = 24 N = 20
Creatinine mg/di 0.75 0.01 0.76 0.01 0.73 0.01
Calcium mg/di 8.7 0.2 9.8 0.2 10.0 0.l
Phosphorus mg/di 11.8 0.6 7.8 0.3a 7.7 0.3a
PTH pg/mi
Calcitriol pg/mi
3 10 24
103 13
87 6
82 10
107 l5
220 23ab
Advanced renal
failure (N — 77) N = 48 N = 16 N — 13
Creatinine mg/di 1.07 0.02 1.06 0.05 1.00 0.04
Calcium mg/di 7.0 0.2 9.9 o.2 98 o.2
Phosphorus mg/di 16.4 0.7 7.7 0.4a 79 0.2a
PTHpg/ml
Calcitriol pg/mi
410 24
52 13
114 l4
55 8
138 l7
230
Data are: mean SE ; N = number of rats.
ap<005vs HPDb p < 0.05 vs. HCaD
C Total PTH measurements = 378; respective numbers in each group
starting with normal renal function were 127, 120, 66 and 65.
d Total calcitriol measurements = 171 ; respective numbers in each
group starting with normal renal function were 46, 62, 36 and 27.
groups (P < 0.001). As shown in Table 2, urinary calcium
excretion was greater in the HCaD than the HPD group (P <
0.05); urinary phosphorus was greater in the HPD than the
other two groups (P < 0.01) and greater in the MCaPD than the
HCaD group (P < 0.01). The tubular reabsorption of phospho-
rus (TRP) was less in the HPD than the other two groups (P <
0.001), and lower in the MCaPD than the HCaD group (P <
0.01).
In rats with mild renal failure , serum calcium was not
different among the three groups (Table 1); however, serum
phosphorus was greater in the HPD than the other two groups
(P < 0.001). Although all three groups developed 2° HPT, the PTH
level was approximately twofold higher in the HPD group (P <
0.001). The serum calcitriollevel was highest in the MCaPD group
but was also greater in the HPD than the HCaD group (P <0.001).
As shown in Table 2, urinary calcium excretion was greater in the
HCaD group than the HPD group (P < 0.05). Urinary phosphorus
was greater in the HPD than the other two groups (P < 0.01) and
greater in the MCaPD than the HCaD group (P < 0.01). The
TRP was less in the HPD than the other two groups (P < 0.001),
and lower in the MCaPD than the HCaD group (P < 0.01).
As shown in Figure 1, the CR to PTH in rats with mild renal
failure was greater in the HCaD than in the MCaPD and HPD
groups (9.1 0.8, 7.3 0.3 and 2.5 0.6 mg/dl, respectively,
P < 0.001); furthermore, it was also greater in the MCaPD than
Table 2. Urinary data
HPD HCaD MCaPD
Normal renal function
Calcium mg/24 hr
Calcium/creatinine
0.14 0.03
0.019 0.003
1.13 0.3
0.13 0.1l
0.28 0.08"
0.039 0.0l'
Phosphorus mg/24 hr
Phosphorus/creatinine
70 6
11 1.2
4 l
0.7 0.la
20 2ab
3.3 0.2a
TRP % 37 8 96 l 83 1ab
cAMP pmoi/min 73 4 57 4a 61 3
Creatinine clearance 1.10 0.09 1.18 0.06 1. 13 0.07
mi/mm
Mild renal failure
Calcium mg/24 hr 0.17 0.02 0.88 0.3a 0.48 0.2
Calcium/creatinine 0.019 0.004 0.063 0.02k 0.038 0.01
Phosphorus mg/24 hr
Phosphorus/creatinine
77 7
9.7 0.5
8 l
1 0.la
233 0.3'
TRP % 13 5 88 4 76
Creatinine clearance 0.80 0.05 0.85 0.08 0.81 0.09
mi/mm
Data are mean SE; N = 8 in each group. Abbreviations are: TRP,
tubular reabsorption of phosphorus.
ap< •5 vs. HPD
b p < 0.05 vs. HCaD
12
10
E 8
I:
2
0
HPD HCaD MCaPD
Fig. 1. Caicemic response to PTH mnfusmon. Delta calcium is the
calcemic response to PTH and represents the difference between the
post-PTH infusion and the basal serum calcium. Rats with mild renal
failure (serum creatinine 0.4 to 0.6 mg/dl) were infused for 48 hours with
1-34 rat PTH via a subcutaneously implanted miniosmotic pump. Each
bar represents the different study diets (HPD, high phosphorus diet,
HCaD, high calcium diet, MCaPD, moderate calcium-moderate phos-
phorus diet). *J < 0.05 vs. HPD; #P < 0.05 vs. HCaD.
in the HPD group (P < 0.001). In normal rats maintained on a
moderate calcium and phosphorus diet (MCaPD), the CR to
PTH was 8.5 0.5 mg/dl. This value was significantly greater
than both the MCaPD and HPD groups with mild renal failure.
In moderate renal failure, the HPD group first developed
fasting hypocalcemia and hyperphosphatemia increased at this
stage of renal failure (Table 1). Serum calcium was less (P <
0.001) and serum phosphorus greater (P < 0.001) in the HPD
than the other two groups. The serum PTH level was elevated
in all three groups (Table 1) but was approximately threefold
greater in the HPD group (P < 0.001). The serum calcitriol level
was normal in the MCaPD group and similarly decreased in the
HPD and HCaD groups (P < 0.00 1).
In advanced renal failure, the fasting serum calcium was less
(P < 0.001) and serum phosphorus greater (P < 0.001) in the
I
0
C.)
C)
E
a)
Cl)
Fig. 2. Intragroup comparisons of serum
calcium and calcitriol. A. The intragroup
comparison (same study diet) for serum
calcium is shown for each of the four stages
of renal function. B. The intragroup
comparison (same study diet) for serum
calcitriol is shown for each of the four stages
of renal function. For Figure 2, the lowest
serum creatinine is the top row and the
highest serum creatinine is the bottom row.
The number inserted at the top of each bar is
the mean value for the group (HPD, high
phosphorus diet; HCaD, high calcium diet;
MCaPD, moderate calcium-moderate
phosphorus diet). *R < 0.05 vs. preceding
lower serum creatinine level.
HPD than the other two groups (Table 1). Although 2° HPT was
present in all three groups, PTH levels were three- to four-fold
greater in the HPD group than the other two groups (P < 0.001).
In the MCaPD group, serum calcitriol levels remained in the
normal range and were greater than in the HCaD and HPD
groups (P < 0.001).
Shown in Figures 2 and 3 are the intragroup comparisons for
the different dietary groups for the four different levels of renal
function. In the HPD group, serum calcium progressively
decreased in moderate and advanced renal failure (P < 0.001).
Serum phosphorus and PTH progressively increased at each
stage of renal failure (P < 0.001). The PTH level was approxi-
mately nine-fold greater in advanced renal failure than in
normal rats. Serum calcitriol decreased progressively as renal
function deteriorated (P < 0.001) and was approximately 25%
of normal in advanced renal failure. As shown in Table 3,
significant positive correlations were observed between the
serum creatinine and serum PTH, phosphorus, calcitriol, and
calcium. Moreover, serum PTH correlated with serum phos-
phorus and inversely correlated with calcitriol and calcium.
The intragroup comparison for the HCaD shows that the
serum calcium and phosphorus were similar at every level of
renal function (Figs. 2 and 3). Serum PTH increased in mild
renal failure and the increment was greater in advanced renal
failure (P < 0.001). Serum calcitriol decreased in mild renal
failure and was lower in advanced renal failure (P < 0.001). As
shown in Table 3, serum PTH correlated with creatinine and
inversely correlated with calcitriol. Serum calcitriol was in-
versely correlated with serum creatinine.
The intragroup comparison for the MCaPD reveals that
although serum calcium, phosphorus and calcitriol did not
change at any level of renal function (Figs. 2 and 3), serum PTH
progressively increased (P < 0.001). As shown in Table 3, PTH
only correlated with serum creatinine (r = 0.74, P < 0.001). Of
interest was the finding that when serum creatinine and the CR
to PTH were compared in normal rats and rats with mild renal
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Fig. 3. Intragroup comparisons of serum
phosphorus and PTH. A. The intragroup
comparison (same study diet) for serum
phosphorus is shown for each of the four
stages of renal function. B. The intragroup
comparison (same study diet) for serum PTH
is shown for each of the four stages of renal
function. For Figure 3, the lowest serum
creatinine is the bottom row and the highest
serum creatinine is the top row. The number
inserted at the top of each bar is the mean
value for the group (HPD, high phosphorus
diet; HCaD, high calcium diet; MCaPD,
moderate calcium.moderate phosphorus diet).
*P < 0.05 vs. preceding lower serum
creatinine level.
failure, a significant correlation was observed (r =
—0.60, P <
0.02).
The PTH-creatinine regression lines for each diet are shown
in Figure 4. The slope of the line was significantly greater in the
HPD group than in the MCaPD and HCaD groups (P < 0.001;
t-test with Bonferroni correction).
Discussion
The results of these studies emphasize that the rat is an
excellent model to study the development of 2° HPT in renal
failure even during the relatively short 16 to 20 day time period
used in this study. The relative importance of the pathogenic
factors in the development of 2° HPT would appear to depend
on the dietary calcium and phosphorus content and the magni-
tude of renal failure. With the HPD, which induced the most
severe 2° HPT at every level of renal function, 2° HPT could be
attributed to the cumulative effect of factors which included
phosphorus retention, a calcitriol deficiency, a decreased SCR to
PTH, and eventually hypocalcemia. For the HCaD, the genesis
of 2° HPT could be best attributed to a deficiency of calcitriol.
For the MCaPD, a decreased CR to PTH appeared to be the
primary factor responsible for the development of 2° HPT. Our
results emphasize that even with the same degree of renal
failure, the relative contribution of each pathogenic factor to the
development of 2° HPT may vary considerably. The current
study may also help to explain why in previous studies which
have evaluated the development of 2° HPT in early renal failure,
serum calcitriol levels have been reported as decreased or
normal [25, 26], and sometimes even elevated [7, 27]. More-
over, detailed information on the importance of the CR to PTH
in the development of 2° HPT which were lacking in early renal
failure are provided in the present study.
High phosphorus diet
The HPD has been used as the traditional method for the
induction of 2° HPT in renal failure [10, 11, 24] and induced the
most severe 2° HPT in the current study. Factors identified with
phosphorus-loading and the induction of 2° HPT in renal failure
have included a reduction in calcitriol [28], a decreased CR to
PTH [10, 14], and hypocalcemia [1, 2, 10]. Thus, the effect of
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Cr PTH CTR P Ca
High phosphorus diet (HPD)
Creatinine Cr, mg/di —
PTH pg/mi 0.85a
Calcitriol CTR, pg/mi o.78°
Phosphorus P, mg/di 0.77a 0.85a 0.61a
Calcium Ca, mg/dl 0.90a 0.76a
High calcium diet (HCaD)
Creatinine mg/dl —
PTH pg/mi 0.71°
Calcitriol pg/mi —0.61° —0.55° —
Phosphorus mg/di 0.00 0.12 038b
Calcium mg/dl 0.12 —0.02 0.30 0.18 —
Moderate calcium-moderate
phosphorus diet (MCaPD)
Creatinine mg/di —
PTH pg/mi 0.74a
Calcitnol pg/mi 0.25 0.28 —
Phosphorus mg/dl —0.24 —0.16 0.09 —
Calcium mg/dl 0.16 —0.04 0.08 —0.22 —
phosphorus-loading has not been attributed to a direct effect on
PTH synthesis and secretion. However, preliminary data from
a recent study suggest the possibility that phosphorus may
directly stimulate P1'H mRNA [29].
In rats with normal renal function, the HPD diet resulted in
both higher PTH and urinary cyclic AMP levels, the latter a
biological marker of PTH activity. Others have also shown that
a high phosphorus diet can induce 2° HPT in normal animals
[30]. While hypocalcemia was not observed in the fasting state
in the present study, data from Portale et al have shown that
phosphorus-loading can induce mild hypocalcemia when serum
calcium values are obtained throughout the day [15]. Thus, the
possibility that hypocalcemia contributed to the development of
2° HPT should be considered. The normal serum calcitriol level
in the presence of phosphorus loading and high PTH levels was
likely due to the fact that the inhibitory effect of phosphorus
was counteracted by the stimulatory effect of PTH [31]. Fur-
thermore, the decreased serum phosphorus level was likely due
to high PTH levels in the fasting state.
During studies in mild renal failure, PTH levels increased by
approximately three-fold. Important findings at this level of
renal function which likely contributed to the development of 2°
HPT were an increase in serum phosphorus, a decrease in
serum calcitriol, the likelihood of hypocalcemia during the
course of the day [15], and a markedly decreased CR to PTH;
the latter reflects an abnormal response to PTH which requires
an additional increment in PTH to maintain a specific serum
calcium level.
In moderate and advanced renal failure, fasting hypocalcemia
was first observed as were further increases in serum phospho-
rus and decreases in serum calcitriol. In advanced renal failure,
serum PTH levels were approximately ten-fold greater than
normal. Hypocalcemia has the potential to increase PTH levels
by directly stimulating PTH mRNA [3, 4] and also due to its
direct stimulation of PTH secretion [32]. Using the same PTH
assay as the current study, Uden et al [33] have reported in
0
0 0.25 0.5 0.75 1 1.25
Serum creatinine, mgldi
Fig. 4. The reiationship between serum PTH and creatinine. Serum
P1'H and creatinine levels are plotted for the entire range of values from
normal renal function to advanced renal failure. Each line represents
the different study diets (high phosphorus diet, — y = —66.4 + 454.2x,
r = 0.85; high calcium diet, — y = 24 + 86.5x, r = 0.71; moderate
calcium-moderate phosphorus diet, y = 4.2 + 138,1x, r = 0.74).
The least squares regression equation for each diet is presented, and the
r value is the correlation coefficient with a P value <0.001 for each
group. The slope of the HPD group is significantly greater than the slope
of the other two groups (P < 0.001).
normal rats that maximal PTH levels induced by hypocalcemia
were approximately 2.5 times greater than basal PTH levels.
Thus, the ten-fold increase in PTH in the present study must be
due to the cumulative effect of factors other than the effect of
hypocalcemia on PTH secretion. The presence of a calcitriol
deficiency has been shown to increase the transcription of PTH
mRNA [4, 6]; at the same time, uremia has been shown to
decrease the density of the cytosolic vitamin D receptor [34, 35]
and may even decrease the binding of the vitamin D receptor
with the vitamin D responsive element of the PTH gene [36].
In the HPD group, significant positive correlations were
observed between both PTH and phosphorus and the serum
creatinine, and significant inverse correlations between both
calcitriol and calcium and the serum creatinine. Moreover,
serum PTH correlated with serum phosphorus and inversely
correlated with calcitriol and calcium. Our data indicate that the
induction of severe 2° HPT by a HPD is through the interaction
of additive factors which include hypocalcemia, phosphorus
retention, a deficiency of calcitriol, and a decreased CR to PTH.
Thus, high dietary phosphorus is an extremely important factor
in the genesis of 2° HPT because it inhibits all the counter-
regulatory mechanisms which may moderate the severity of 2°
HPT.
High calcium diet
As shown by the urinary calcium data in normal rats and in
rats with mild renal failure, the HCaD produced calcium-
loading. However, a somewhat unexpected finding was that the
HCaD also resulted in a decrease in urinary phosphorus excre-
tion despite a similar dietary phosphorus content as the
MCaPD; this finding was likely due to some phosphorus binding
by calcium in the gut.
The HCaD in normal rats resulted in a significant reduction in
calcitriol which was likely due to the known inhibitory effect of
a high calcium intake on calcitriol production (20, 31). Despite
lower calcitriol levels, PTH did not increase. This was likely
Table 3. Pearson's coefficients of correlation (r value) for each diet
during the entire range of values from normal renal function to
advanced renal failure
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due to the suppressive effect of dietary calcium-loading on PTH
synthesis and secretion, thus, the tendency to develop hyper-
calcemia is counteracted by a reduction in PTH which increases
the urinary excretion of calcium. Furthermore, at the molecular
level, calcium-loading has been shown to decrease PTHmRNA
[371 and most recently, to up-regulate the vitamin D receptor in
the parathyroid gland [38].
In mild renal failure, PTH levels increased by almost twice
and calcitriol decreased further. Serum calcium and phosphorus
were normal as was the CR to PTH. Since both the urinary
phosphorus excretion and the TRP reflect mild phosphorus
restriction, it is unlikely that phosphorus retention contributed
to the development of 2° HPT. Supporting the concept that a
calcitriol deficiency is important for the development of 2° HPT
is the study by Lopez-Hilker et al in which even hypercalcemia
did not prevent the development of 2° HPT in azotemic dogs
when a calcitriol deficiency was present [39]. Furthermore, the
marked decrease in calcitriol levels in mild renal failure was
observed despite elevated PTH levels and moderate dietary
phosphorus restriction. Thus, essentially the same PTH level
and even greater dietary phosphorus restriction was present in
the HCaD than the MCaPD group, and nevertheless the
MCaPD group was able to maintain normal calcitriol levels.
Consequently, it must be concluded that dietary calcium-
loading is an important inhibitor of calcitriol synthesis and this
was the only factor which could be shown to induce 2° HPT in
the HCaD group. Moreover, the magnitude of the effect of a
calcitriol deficiency on the genesis of 2° HPT is difficult to
assess because calcium-loading inhibits PTH secretion.
In moderate renal failure, the PTH and calcitriol levels were
not different than those observed in mild renal failure, while in
advanced renal failure calcitriol decreased and PTH increased
further. Among the three dietary groups, the transition from
mild to moderate renal failure in the HCaD group was the only
instance in which PTH did not increase as renal function
decreased. The finding of similar calcitnol levels is consistent
with our hypothesis that a calcitriol deficiency is the primary
factor in the genesis of 2° HPT in this group.
Moderate calcium and phosphorus diet
In rats receiving a MCaPD, PTH levels almost doubled in
mild renal failure, despite normal serum calcium, phosphorus,
and calcitriol levels. The only apparent factor contributing to
the development of 2° HPT was a decreased CR to PTH.
However, it is difficult to be absolutely certain that the reduc-
tion in renal function did not result in phosphorus retention.
Despite urinary phosphorus excretion was less than one-third of
the HPD, it is possible that some degree of phosphorus reten-
tion was present. However, against significant phosphorus
retention contributing to the development of 2° HPT are several
findings that include: (1) the baseline TRP which was 83% on a
0.6% phosphorus diet, considered to be the lower limits of
recommended dietary phosphorus [22], was not much lower at
76% in mild renal failure; since both high PTH levels and renal
failure independent of PTH increase phosphorus excretion, the
7% decrease in TRP does not suggest significant phosphorus
loading; and (2) contrasting findings in rats with advanced renal
failure on the MCaPD with those in mild renal failure on the
HPD reveals that the MCaPD group was able to maintain a
normal serum calcitriol level despite a more severe reduction in
renal mass. Conversely, despite a similar three-fold increase in
P1'H, calcitriol levels were decreased on the HPD even in mild
renal failure. Finally, indicating that the decreased CR to P'FH
was not due to phosphorus-loading in the MCaPD group are our
results in a recent study in which we have shown that the CR to
PTH in mild renal failure was decreased despite the use of a
phosphorus-restricted (0.2%) diet (unpublished observations).
Thus, it would appear unlikely that significant phosphorus
retention was present on the MCaPD in mild renal failure.
Even though normal serum calcitriol levels were present at all
stages of renal function in rats receiving a MCaPD, it is possible
that resistance to the suppressive effect of normal calcitriol
levels on PTH transcription may have contributed to the
development of 2° HPT. While calcitriol resistance has been
described in advanced renal failure [40], information is not
available on whether calcitriol resistance is present in mild renal
failure. The finding of a normal serum calcitriol in all stages of
renal failure was somewhat unexpected, but Fukagawa et al
have reported similar calcitriol results in 7/8 nephrectomized
rats on the same diet as our MCaPD [41]. Thus, it is likely that
the stimulus of a potentially mildly restrictive calcium and
phosphorus diet together with elevated PTH levels in the
presence of normal renal tissue in the remnant kidney was
responsible for the normal serum calcitriol level. However, as
we have observed, serum calcitriol levels decreased after a
longer duration of renal failure despite the same diet and similar
PTH levels [42]. Thus, it is likely that intrinsic renal disease
develops in the remnant kidney with time and impairs calcitriol
production.
Calcemic response to PTH
In the present study, the CR to PTH in rats with mild renal
failure was normal with the HCaD, modestly decreased with the
MCaPD, and markedly decreased with the HPD. While the CR
to PTH was normal in the HCaD group, it must be considered
to be due to the calcium content of the diet during the PTH
infusion because the CR to PTH for the same rats on a
calcium-free diet was lower during the PTH infusion (9.1 .8
vs. 6.5 .6 mg/dl, P < 0.02, unpublished data). In the present
study, a reduction in the CR to PTH would not appear to
contribute to the development of 2° HPT in the HCaD group,
but would be relevant for the MCaPD and HPD groups. Factors
such as phosphorus retention [10, 14], decreased calcitriol
levels [8], and down-regulation of PTH receptors [11, 43] have
all been reported to contribute to the decreased CR to PTH in
renal failure. In the HPD group, all these factors likely contrib-
uted to the decreased CR to PTH. However, in the MCaPD
group, a decreased CR to PTH was observed despite a normal
serum calcitriol level and minimal if any phosphorus retention.
Down-regulation of PTH receptors due to an increase in PTH
levels has been stated to be a cause of a decreased CR to PTH
in renal failure [43]. However, in our view, this is an unlikely
explanation in the MCaPD group since, by definition, lown-
regulation should only play a role in the development of 2° HPT
if PTH is first increased by other means. Moreover, in a recent
report in which PTH levels were reduced to the normal range in
azotemic rats, we have shown that the CR to PTH remained
decreased in azotemic rats [44]. Furthermore, phosphorus
retention is also unlikely to be the causative factor since we
have observed a decreased CR to PTH in rats with mild renal
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failure on a 0.2% phosphorus diet (unpublished observations).
Thus, our data in the MCaPD group suggest the possibility that
a factor intrinsic to uremia was responsible for the abnormal CR
to PTH. Moreover, this is the first time that the CR to PTH has
been reported to be decreased in mild renal failure in the
presence of normal serum calcitriol levels. The concept that
resistance to PTH is an important factor in uremia is also
suggested by studies which have shown that high PTH levels
are required to maintain a normal bone formation rate in
dialysis patients [45, 46]. In a recent study, Sherrard et al
questioned whether uremia-induced deficiencies in trophic fac-
tors, excesses of growth inhibitors, or receptor or post-receptor
defects lead to this resistance [46]. Additional support for the
concept that uremia induces hormonal resistance can be de-
rived from other studies in which resistance to other peptide
hormones such as insulin and growth hormone has been re-
ported in uremia [47, 48] and even in the early stages of renal
failure [49].
In conclusion, results from this study document that the rat is
an excellent model to study the development of 2° HPT during
the graded reduction in renal function. This comprehensive
study in 453 rats has demonstrated that varying the dietary
content of calcium and phosphorus can serve to separate
individual factors important for the development of 2° HPT and
has provided extensive data on the relative importance of
factors which contribute to the development of 2° HPT in renal
failure. As such, this large body of integrated information can
be used as a framework for future investigators to focus on
more specific areas in which intact animal studies can be
combined with molecular biological techniques to evaluate the
interaction of calcitriol, phosphorus, and calcium on the tran-
scription of PTH mRNA and the vitamin D receptor. Further-
more, this study highlights the necessity for studies to evaluate
the mechanisms by which uremia affects the development of 2°
HPT.
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